Kantar Health in Drug Safety Data Partnership

Kantar Health has partnered with Tel Aviv-based technology company Data2Life, to mine big data sources and deliver better information on drug safety.

Data2Life aggregates, standardizes and validates data from regulatory agencies (including the US Food and Drug Administration and Health Canada), anonymized electronic health records (EHR) and social media. Through a partnership with health maintenance organization Clalit Health Services, the firm has access to anonymized records from a centralized EHR system that includes almost two decades of data on more than 4.5 million patients. These records include twenty years of longitudinal data from inpatient, outpatient, pharmacy, lab and imaging sources.

Through the deal with Kantar Health, the two firms will combine multi-layered data with machine learning and analysis, to provide early intelligence on drug side effects. Kantar Health will use this to help clients meet regulatory requirements for adverse event reporting, refine clinical trial designs for targeted populations or new indications for existing products, and gain insights into how drugs perform relative to other products from a safety perspective.

Jeremy Brody (pictured), EVP, Kantar Health, explains: 'Adverse-event reporting is a vital function for pharma and biotech companies... Data2Life collects data from multiple real-world sources, and our partnership allows us to help pharma harness the power of these data to address their safety and surveillance issues, as well as better focus development resources and foster innovations that can vastly improve patient quality of life'.

Web sites: www.kantarhealth.com and www.data2life.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Kantar Health
• All news